BMY/JNJ/BAYN: Bayer AF failure does not reduce chances for Factor XI in stroke

Bayer announced Monday that its Factor XIa phase III trial of asundexian to prevent strokes in high risk patients with atrial fibrillation (OCEANIC-AF) was stopped early by its independent data monitoring committee due to lack of efficacy, leading the stock to have discounted the entire asundexian program. However, despite this failure in the prevention of strokes caused by atrial fibrillation, we continue to believe BMY/JNJ factor XI milvexian will be successful in preventing the common form of stroke, non-cardiogenic ischaemic stroke...